Leclere 2024 — Gene Therapy Hearing Loss: Non-Viral Vectors
Full title: Gene therapy for hearing loss: Current status and future prospects of non-viral vector delivery systems
Journal: Hearing Research (2024)
Authors: Leclere et al.
RAG book name: Leclere_2024_Gene-therapy-hearing-loss-nonviral-vectors_HeaRes
Why It Matters for Misha
AAV-based therapies have a key limitation: once you’ve been treated, pre-existing immunity makes re-treatment with AAV very difficult. Non-viral vectors (lipid nanoparticles, polymeric nanoparticles, electroporation) don’t have this problem. Important for thinking about Misha’s long-term treatment strategy.
Key Findings
- Current gap: Hearing aids, ossiculoplasty, cochlear implants — don’t address the genetic cause, limited in noise
- AAV dominates cochlear gene therapy due to excellent diffusion and sensory cell compatibility
- AAV drawbacks: immunogenicity (blocks re-dosing), manufacturing complexity, packaging limit (~4.7 kb), high cost
- Non-viral alternatives reviewed:
- Cationic lipids / lipid-based nanoparticles (LNPs)
- Polymeric nanoparticles
- Electroporation
- Each has advantages/limitations for inner ear delivery
- Key advantage of non-viral: no immune priming → repeated administration possible
- Limitation: lower transfection efficiency than AAV in sensory cells (current challenge)
Strategic Relevance
- STRC cDNA is 5430 bp = already at the edge of AAV capacity
- If initial AAV therapy has partial effect, re-dosing with non-viral vectors could supplement
- The field is actively developing alternatives
Connections
- Gadenstaetter 2024 - Inner Ear Gene Therapy Overview — AAV limitations discussed there [see-also]
- Iranfar 2026 - Dual AAV STRC DFNB16 — AAV-based approach this complements [see-also]
- STRC Gene Therapy Research [applies]